⌕
Novavax · NVAX · Nasdaq
Tenet 37 · Weak
Compare
$8.06−5.45%At closeTenet 37 · Weak
$8.06−0.47 (−5.45%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Novavax (NVAX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 11, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Novavax to Participate in Jefferies London Healthcare Conference

GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London Healthcare Conference…

● Zacks Investment ResearchNov 10, 2026 · 10:01 ET
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…

● Zacks Investment ResearchNov 6, 2026 · 11:02 ETEARNINGS EXPECTED BY FEB 4
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.…

● MarketBeatNov 6, 2026 · 05:15 ETEARNINGS EXPECTED BY FEB 4
Novavax Q3 Earnings Call Highlights

Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine …

● Seeking AlphaNov 5, 2026 · 13:54 ETEARNINGS EXPECTED BY FEB 4
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript

Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 5, 2026 · 10:37 ETEARNINGS EXPECTED BY FEB 4
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.…

● PRNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 4
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights

Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidan…

● Zacks Investment ResearchOct 29, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 4
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● PRNewsWireOct 29, 2026 · 09:37 ETCOMPANY'S OWN WORDS
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose …

● PRNewsWireOct 29, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 4
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Th…

● 24/7 Wall StreetOct 28, 2026 · 12:04 ET
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock sta…

● Zacks Investment ResearchOct 26, 2026 · 18:46 ET
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know

Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.…

● Zacks Investment ResearchOct 21, 2026 · 10:00 ET
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.…

● Zacks Investment ResearchOct 19, 2026 · 18:46 ET
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors

Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.…

● Defense WorldOct 18, 2026 · 02:21 ET
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened

Novavax, Inc. (NASDAQ: NVAX - Get Free Report) shares traded down 9.1% during trading on Friday. The stock traded as low as $11.57 and last traded at $11.6480. Approximately 2,002,169 shares traded hands during trading, …

● ReutersOct 16, 2026 · 17:24 ET
Novavax shareholder Shah Capital to step back from activist role

Novavax shareholder Shah Capital to step back from activist role…

● BarronsOct 16, 2026 · 15:36 ET
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.…

● 24/7 Wall StreetOct 16, 2026 · 12:44 ET
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developer…

● Zacks Investment ResearchOct 13, 2026 · 18:45 ET
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.…

● Zacks Investment ResearchOct 12, 2026 · 12:16 ET
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.…

● 24/7 Wall StreetOct 9, 2026 · 13:59 ET
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%.…

● Zacks Investment ResearchOct 9, 2026 · 10:01 ET
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.…

● Defense WorldOct 7, 2026 · 08:21 ET
Novavax (NASDAQ:NVAX) Stock Jumps 10.5% – Should You Buy?

Shares of Novavax, Inc. (NASDAQ: NVAX - Get Free Report) were up 10.5% during mid-day trading on Monday. The company traded as high as $11.25 and last traded at $11.5620. 3,160,292 shares changed hands during mid-day tra…

● Zacks Investment ResearchOct 6, 2026 · 18:45 ET
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novavax (NVAX) closed at $11.27, marking a -10.31% move from the previous day.…

● BenzingaOct 6, 2026 · 10:18 ET
Novavax Stock Falls Back: What's Going On?

Novavax Inc. (NASDAQ:NVAX) shares are pulling back Tuesday after a more than 20% surge Monday. Vaccine stocks rallied after a suspected pneumonic plague case in Russia.…

● PRNewsWireSep 2, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Novavax to Participate in September Investor Conferences

GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Confere…

● PRNewsWireAug 28, 2026 · 08:30 ET
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to g…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 4. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just NVAX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.